|
|
|
|
|
|
Development of a CNS Entry Strategy: Health Advances assisted a large pharmaceutical company interested in increasing its CNS presence through licensing and
acquisition with a comprehensive review of the CNS space and the development of a CNS strategy. After reviewing the spectrum of CNS indications, Health Advances conducted
interviews with top thought leaders and completed a scientific/clinical literature review in order to perform a deep and careful investigation into six high-priority areas:
Alzheimer's, Parkinson's, schizophrenia, neuropathic pain, insomnia, and depression. This investigation evaluated targets, mechanisms, and pipeline for clinical utility and
commercial potential. We also identified key unmet needs and the state of current clinical practice for each disease.
Ischemic Stroke: Health Advances assisted a large public company prepare a commercial development plan for acute ischemic stroke. At the time of the project,
the client's product was in late stage clinical development and was expected to receive FDA approval shortly thereafter. Health Advances interviewed numerous cardiologists
and neurologists with experience as investigators in clinical trials for ischemic stroke. Integrating unmet needs, competitive positioning, development timing, and possible
label claims, the Health Advances team refined the product development plan.
Neurologic Testing: An esoteric reference lab asked Health Advances to investigate the utility of various esoteric lab tests marketed to neurologists to
facilitate differential diagnosis of diseases exhibiting similar symptoms such as muscular dystrophy versus ataxia. The project forecasted the demand for the high-margin
panels in light of changing referral patterns, managed care pressures, and pioneering therapeutics in development.
Neurotechnology for Brain Stimulation: An early-stage company was developing a neurotechnology device to detect neural signals and stimulate the brain.
The primary application was spinal cord injury but the technology was applicable to many other disease areas. The client asked Health Advances to help determine the
first group of applications upon which it should initially focus, the most interesting of which was Alzheimer's disease. All potential applications were screened and
10-12 indications were prioritized for initial development.
Parkinson's Disease: Health Advances worked with a client on the formation of a new company to complete the development of a novel compound that could
potentially slow progression of Parkinson's disease. In addition to examining the market opportunity, we also explored issues around the predictability of preclinical
disease models, the utility of disease scores for evaluating clinical performance, and other possible endpoints for clinical development.
|
|
 |
|
|
|
|
